Search

Your search keyword '"Devasia, Theresa"' showing total 165 results
Start Over Author "Devasia, Theresa"
165 results on '"Devasia, Theresa"'

2. Cannabis Use in Patients Seen in an Academic Radiation Oncology Department

Author

Cousins, Matthew M., Mayo, Chuck, Devasia, Theresa, Dykstra, Michael, Regan, Samuel, Miller, Sean, Allen, Steven G., Bryant, Alex K., Morales-Rivera, Krystal, Herr, Daniel J., Edwards, Donna M., Takayesu, Jamie, Birer, Samuel, Egerer, Nancy, Evans, Joseph, Elliott, David, Henderson, Caitlin, Laucis, Anna M., McFarlane, Matthew, Dragovic, Aleksandar F., Shah, Jennifer, Hayman, James A., Coughlin, Lara N., Ilgen, Mark, and Jagsi, Reshma

Published
2023
Full Text
View/download PDF

3. Prevalence of cancer survivors in the United States.

Author

Tonorezos, Emily, Devasia, Theresa, Mariotto, Angela B, Mollica, Michelle A, Gallicchio, Lisa, Green, Paige, Doose, Michelle, Brick, Rachelle, Streck, Brennan, Reed, Crystal, and Moor, Janet S de

Subjects
*CANCER survivors, *POPULATION aging, *CANCER diagnosis, *MORTALITY, *FEMALES
Abstract

Background With aging of the population and improvements in diagnosis, treatment, and supportive care, the number of cancer survivors in the United States has increased; updated prevalence estimates are needed. Methods Cancer prevalence on January 1, 2022, was estimated using the Prevalence Incidence Approach Model, utilizing incidence, survival, and mortality. Prevalence by age decade, sex, and time from diagnosis was calculated. The percentage of cancer survivors in the projected US population by age and sex was calculated as the ratio of the sex-specific projected prevalence to the sex-specific projected US population. Results There were an estimated 18.1 million US cancer survivors as of January 1, 2022. From 2022 to 2030, the number of US cancer survivors is projected to increase to 21.6 million; by 2040, the number is projected to be 26 million. Long-term survivors are highly prevalent; in 2022, 70% of cancer survivors had lived 5 years or more after diagnosis, and 11% of cancer survivors had lived 25 years or more after diagnosis. Among all US females aged 40-54 years, 3.6% were cancer survivors; among females aged 65-74 years, 14.5% were cancer survivors; among females aged 85 years and older, 36.4% were cancer survivors. Among all US males aged 40-54 years, 2.1% were cancer survivors; among males aged 65-74 years, 16% were cancer survivors; and among those aged 85 years and older, 48.3% were cancer survivors. Conclusions Cancer survivors are growing in number. In the United States, most cancer survivors are long-term and very long-term survivors, representing a substantial proportion of the US population. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

28. Increase in the Life Expectancy of Patients with Cancer in the United States.

Author

Devasia, Theresa P., Howlader, Nadia, Dewar, Ron A., Stevens, Jennifer L., Mittu, Karen, and Mariotto, Angela B.

Abstract

Background: Cancer is becoming more of a chronic disease due to improvements in treatment and early detection for multiple cancer sites. To gain insight on increased life expectancy due to these improvements, we quantified trends in the loss in expectation of life (LEL) due to a cancer diagnosis for six cancer sites from 1975 through 2018. Methods: We focused on patients diagnosed with female breast cancer, chronic myeloid leukemia (CML), colon and rectum cancer, diffuse large B-cell lymphoma (DLBCL), lung cancer, or melanoma between 1975 and 2018 from nine Surveillance, Epidemiology, and End Results cancer registries. Life expectancies for patients with cancer ages 50+ were modeled using flexible parametric survival models. LEL was calculated as the difference between general population life expectancy and life expectancy for patients with cancer. Results: Over 2 million patients were diagnosed with one of the six cancers between 1975 and 2018. Large increases in life expectancy were observed between 1990 and 2010 for female breast, DLBCL, and CML. Patients with colon and rectum cancer and melanoma had more gradual improvements in life expectancy. Lung cancer LEL only began decreasing after 2005. Increases in life expectancy corresponded with decreases in LEL for patients with cancer. Conclusions: The reported gains in life expectancy largely correspond to progress in the screening, management, and treatment of these six cancers since 1975. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

33. Supplementary Table IV from Low-Dose Hsp90 Inhibitor Selectively Radiosensitizes HNSCC and Pancreatic Xenografts

Author

Mehta, Ranjit K., primary, Pal, Sanjima, primary, Kondapi, Koushik, primary, Sitto, Merna, primary, Dewar, Cuyler, primary, Devasia, Theresa, primary, Schipper, Matthew J., primary, Thomas, Dafydd G., primary, Basrur, Venkatesha, primary, Pai, Manjunath P., primary, Morishima, Yoshihiro, primary, Osawa, Yoichi, primary, Pratt, William B., primary, Lawrence, Theodore S., primary, and Nyati, Mukesh K., primary

Published
2023
Full Text
View/download PDF

34. Supplementary Methods from Low-Dose Hsp90 Inhibitor Selectively Radiosensitizes HNSCC and Pancreatic Xenografts

Author

Mehta, Ranjit K., primary, Pal, Sanjima, primary, Kondapi, Koushik, primary, Sitto, Merna, primary, Dewar, Cuyler, primary, Devasia, Theresa, primary, Schipper, Matthew J., primary, Thomas, Dafydd G., primary, Basrur, Venkatesha, primary, Pai, Manjunath P., primary, Morishima, Yoshihiro, primary, Osawa, Yoichi, primary, Pratt, William B., primary, Lawrence, Theodore S., primary, and Nyati, Mukesh K., primary

Published
2023
Full Text
View/download PDF

35. Supplementary Figure from Low-Dose Hsp90 Inhibitor Selectively Radiosensitizes HNSCC and Pancreatic Xenografts

Author

Mehta, Ranjit K., primary, Pal, Sanjima, primary, Kondapi, Koushik, primary, Sitto, Merna, primary, Dewar, Cuyler, primary, Devasia, Theresa, primary, Schipper, Matthew J., primary, Thomas, Dafydd G., primary, Basrur, Venkatesha, primary, Pai, Manjunath P., primary, Morishima, Yoshihiro, primary, Osawa, Yoichi, primary, Pratt, William B., primary, Lawrence, Theodore S., primary, and Nyati, Mukesh K., primary

Published
2023
Full Text
View/download PDF

36. Data from Low-Dose Hsp90 Inhibitor Selectively Radiosensitizes HNSCC and Pancreatic Xenografts

Author

Mehta, Ranjit K., primary, Pal, Sanjima, primary, Kondapi, Koushik, primary, Sitto, Merna, primary, Dewar, Cuyler, primary, Devasia, Theresa, primary, Schipper, Matthew J., primary, Thomas, Dafydd G., primary, Basrur, Venkatesha, primary, Pai, Manjunath P., primary, Morishima, Yoshihiro, primary, Osawa, Yoichi, primary, Pratt, William B., primary, Lawrence, Theodore S., primary, and Nyati, Mukesh K., primary

Published
2023
Full Text
View/download PDF

38. Cannabis Use in Patients Seen in an Academic Radiation Oncology Department

Author

Cousins, Matthew M., primary, Mayo, Chuck, additional, Devasia, Theresa, additional, Dykstra, Michael, additional, Regan, Samuel, additional, Miller, Sean, additional, Allen, Steven G., additional, Bryant, Alex K., additional, Morales-Rivera, Krystal, additional, Herr, Daniel J., additional, Edwards, Donna M., additional, Takayesu, Jamie, additional, Birer, Samuel, additional, Egerer, Nancy, additional, Evans, Joseph, additional, Elliott, David, additional, Henderson, Caitlin, additional, Laucis, Anna M., additional, McFarlane, Matthew, additional, Dragovic, Aleksandar F., additional, Shah, Jennifer, additional, Hayman, James A., additional, Coughlin, Lara N., additional, Ilgen, Mark, additional, and Jagsi, Reshma, additional

Published
2022
Full Text
View/download PDF

41. Cancer treatment and survivorship statistics, 2022

Author

Miller, Kimberly D., primary, Nogueira, Leticia, additional, Devasia, Theresa, additional, Mariotto, Angela B., additional, Yabroff, K. Robin, additional, Jemal, Ahmedin, additional, Kramer, Joan, additional, and Siegel, Rebecca L., additional

Published
2022
Full Text
View/download PDF

42. Pretreatment Levels of Soluble Tumor Necrosis Factor Receptor 1 and Hepatocyte Growth Factor Predict Toxicity and Overall Survival After90Y Radioembolization: Potential Novel Application of Biomarkers for Personalized Management of Hepatotoxicity

Author

Cousins, Matthew M., primary, Devasia, Theresa P., additional, Maurino, Christopher M., additional, Mikell, Justin, additional, Schipper, Matthew J., additional, Kaza, Ravi K., additional, Lawrence, Theodore. S., additional, Cuneo, Kyle C., additional, and Dewaraja, Yuni K., additional

Published
2021
Full Text
View/download PDF

43. PD05-10 TOAD: WARTS AND ALL? SUBGROUP ANALYSES REVEALING DIFFERENTIAL TREATMENT EFFECTS IN THE TIMING OF ANDROGEN DEPRIVATION TRIAL

Author

Stensland, Kristian, primary, Devasia, Theresa, additional, Caram, Megan, additional, Zaslavsky, Alexander, additional, Sparks, Jordan, additional, Chapman, Christina, additional, Burns, Jennifer, additional, Vedapudi, Varsha, additional, Duchesne, Gillian, additional, Tsodikov, Alexander, additional, and Skolarus, Ted, additional

Published
2021
Full Text
View/download PDF

44. Better Understanding the Timing Of Androgen Deprivation Trial Outcomes: Impacts of Prior Androgen Deprivation Therapy.

Author

Stensland, Kristian D, Devasia, Theresa, Caram, Megan E V, Chapman, Christina, Zaslavsky, Alexander, Morgan, Todd M, Hollenbeck, Brent K, Sparks, Jordan B, Burns, Jennifer, Vedapudi, Varsha, Duchesne, Gillian M, Tsodikov, Alexander, and Skolarus, Ted A

Subjects
ANDROGEN deprivation therapy, PROSTATE cancer
Abstract

Background The Timing Of Androgen Deprivation (TOAD) trial found an overall survival benefit for immediate vs delayed androgen deprivation therapy (ADT) for prostate-specific antigen (PSA)–relapsed or noncurable prostate cancer. However, broad eligibility criteria allowed entry of a heterogeneous participant group, including those with prior ADT exposure, raising concerns about subsequent androgen sensitivity. For these reasons, we completed previously specified subgroup analyses to assess if prior ADT was associated with ADT timing efficacy after PSA relapse. Methods We examined TOAD trial patient-level data for participants with PSA relapse after local therapy. We performed Kaplan-Meier analyses for overall survival stratified by prior ADT and randomized treatment arm (immediate or delayed ADT). We compared group characteristics using Mann-Whitney U and Fisher exact tests. All hypothesis tests were 2-sided. Results We identified 261 patients with PSA relapse, 125 of whom received prior ADT. Patients with prior ADT had higher PSA at presentation (12.1 vs 9.0 ng/mL; P  < .001), more cT3 disease (38.4% vs 25.0%; P  =.007), and more likely received radiotherapy as local treatment (80.0% vs 47.8%; P  < .001) but were otherwise similar to patients without prior ADT exposure. Within this prior ADT group, those who received immediate ADT (n = 56) had improved overall survival compared with those who received delayed ADT (n = 69; P  = .02). This benefit was not observed in the group with no prior ADT (P  = .98). Conclusions The survival benefit demonstrated in the TOAD trial may be driven by patients who received ADT prior to trial entry. We provide possible explanations for this finding with implications for treatment of PSA-relapsed prostate cancer and future study planning. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

46. Integrated Survival Estimates for Cancer Treatment Delay Among Adults With Cancer During the COVID-19 Pandemic

Author

Hartman, Holly E., primary, Sun, Yilun, additional, Devasia, Theresa P., additional, Chase, Elizabeth C., additional, Jairath, Neil K., additional, Dess, Robert T., additional, Jackson, William C., additional, Morris, Emily, additional, Li, Pin, additional, Hochstedler, Kimberly A., additional, Abbott, Madeline R., additional, Kidwell, Kelley M., additional, Walter, Vonn, additional, Wang, Ming, additional, Wang, Xi, additional, Zaorsky, Nicholas G., additional, Schipper, Matthew J., additional, and Spratt, Daniel E., additional

Published
2020
Full Text
View/download PDF

47. Low-Dose Hsp90 Inhibitor Selectively Radiosensitizes HNSCC and Pancreatic Xenografts

Author

Mehta, Ranjit K., primary, Pal, Sanjima, additional, Kondapi, Koushik, additional, Sitto, Merna, additional, Dewar, Cuyler, additional, Devasia, Theresa, additional, Schipper, Matthew J., additional, Thomas, Dafydd G., additional, Basrur, Venkatesha, additional, Pai, Manjunath P., additional, Morishima, Yoshihiro, additional, Osawa, Yoichi, additional, Pratt, William B., additional, Lawrence, Theodore S., additional, and Nyati, Mukesh K., additional

Published
2020
Full Text
View/download PDF

48. BRAINSTORM: A Multi-Institutional Phase 1/2 Study of RRx-001 in Combination With Whole Brain Radiation Therapy for Patients With Brain Metastases

Author

Kim, Michelle M., primary, Parmar, Hemant A., additional, Schipper, Matthew, additional, Devasia, Theresa, additional, Aryal, Madhava P., additional, Kesari, Santosh, additional, O’Day, Steven, additional, Morikawa, Aki, additional, Spratt, Daniel E., additional, Junck, Larry, additional, Mammoser, Aaron, additional, Hayman, James A., additional, Lawrence, Theodore S., additional, Tsien, Christina I., additional, Aiken, Robert, additional, Goyal, Sharad, additional, Abrouk, Nacer, additional, Trimble, Malcolm, additional, Cao, Yue, additional, and Lao, Christopher D., additional

Published
2020
Full Text
View/download PDF

49. DCE-MRI Evaluation of 10 patients with brain metastases treated with RRx-001, a Myc inhibitor and a CD47 and PD-L1 downregulator, in a phase I/II trial called BRAINSTORM.

Author

Kim, Michelle Miran, primary, Parmar, Hemant, additional, Aryal, Madhava P, additional, Caroen, Scott, additional, Devasia, Theresa, additional, Schipper, Matthew J, additional, Morikawa, Aki, additional, Spratt, Daniel Eidelberg, additional, Hayman, James, additional, Junck, Larry, additional, Lawrence, Theodore Steven, additional, Lao, Christopher D., additional, and Cao, Yue, additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results